View filters (5 in use)

Updating results

464 results

Sort: Relevance | Date

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

OTL-200 for treating metachromatic leukodystrophy [ID1666]

Proposed [GID-HST10028] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 10 November 2020

Antimicrobial prescribing guideline In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: 08 September 2020

Highly specialised technologies guidance In development

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Highly specialised technologies guidance In development

Metreleptin for treating lipodystrophy (ID861)

In development [GID-HST10011] Expected publication date: TBC

Highly specialised technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Highly specialised technologies guidance In development

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326]

In development [GID-HST10015] Expected publication date: 03 June 2020

Highly specialised technologies guidance In development

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Proposed [GID-TA10554] Expected publication date: TBC

Technology appraisal guidance Proposed

Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

Proposed [GID-TA10555] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treatment-resistant depression (ID1414)

Proposed [GID-TA10371] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Technology appraisal guidance Proposed

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Luspatercept for treating beta-thalassaemia ID1554

Proposed [GID-TA10506] Expected publication date: 16 September 2020

Technology appraisal guidance Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 16 September 2020

Technology appraisal guidance Proposed

Eflornithine with sulindac for treating familial adenomatous polyposis ID1543

Proposed [GID-TA10536] Expected publication date: TBC

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance Proposed

Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Technology appraisal guidance Proposed

Cladribine tablets for treating relapsing–remitting multiple sclerosis [ID2703]

Proposed [GID-TA10548] Expected publication date: 08 January 2020

Technology appraisal guidance Proposed

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery (ID1105)

Proposed [GID-TA10348] Expected publication date: TBC

Technology appraisal guidance Proposed

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Proposed [GID-TA10561] Expected publication date: TBC

Technology appraisal guidance Proposed

Ponesimod for treating relapsing multiple sclerosis [ID1393]

Proposed [GID-TA10556] Expected publication date: TBC

Technology appraisal guidance Proposed

Ofatumumab for treating relapsing multiple sclerosis [ID1677]

Proposed [GID-TA10557] Expected publication date: TBC

Technology appraisal guidance Proposed

Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

Proposed [GID-TA10558] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed